[{"id":"f7fcbd54-143e-4657-9b77-27581b5037f3","acronym":"Morpheus-Liver","url":"https://clinicaltrials.gov/study/NCT04524871","created_at":"2021-01-18T21:40:19.145Z","updated_at":"2025-02-25T15:26:31.453Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","source_id_and_acronym":"NCT04524871 - Morpheus-Liver","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • IO-108 • SAR439459 • imdatifan (NKT2152) • muzastotug (ADG126) • tobemstomig (RG6139)"],"overall_status":"Recruiting","enrollment":" Enrollment 518","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-10"},{"id":"57151d05-381a-48a1-843f-46d3073ad3fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05119335","created_at":"2021-11-15T13:53:41.126Z","updated_at":"2024-07-02T16:35:27.466Z","phase":"Phase 1/2","brief_title":"A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT05119335","lead_sponsor":"NiKang Therapeutics, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imdatifan (NKT2152)"],"overall_status":"Recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 10/26/2021","start_date":" 10/26/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-11-30"}]